课题基金 / 基金详情

"Cancer Immunotherapy by Targeting A2 Adenosine Receptor"

"Cancer Immunotherapy by Targeting A2 Adenosine Receptor"
“针对 A2 腺苷受体的癌症免疫疗法”
批准号:
7100600
负责人:
Michail Sitkovsky
金额:
$22.29万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-05-26 至 2011-04-30

项目摘要

项目成果

Michail Sitkovsky的其他基金

相关文献

中文摘要
翻译
描述(申请人提供):由于抗肿瘤T细胞在实体瘤的免疫抑制微环境中受到抑制,因此认为癌症免疫治疗的应用受到限制。该建议的总体目标是通过灭活抑制肿瘤附近或肿瘤内抗肿瘤T细胞的机制,使癌症免疫治疗更有效。该建议的中心假设是免疫抑制Gs蛋白偶联A2腺苷受体亚型A2A和A2B(分别为A2AR和A2BR)的基因缺失或药理学失活应该阻止抗肿瘤T细胞的抑制,从而促进它们的完全排斥。我们早期的研究发现,A2AR和A2BR在保护正常组织(如肝和肺)免受急性炎症和缺氧区域过度活跃的免疫细胞的影响方面发挥了关键作用,这一假设得到了证实。我们的初步结果证实了这一假设,表明完全或大大改善的排斥大肿瘤在大约
英文摘要
DESCRIPTION (provided by applicant): It is believed that cancer immunotherapy applications are limited because anti-tumor T cells are inhibited in the immunosuppressive microenvironment of solid tumors. The overall goal of this proposal is to render cancer immunotherapies more effective by inactivating mechanisms that inhibit anti-tumor T cells near or within tumors. The central hypothesis of this proposal is that genetic deletion or pharmacological inactivation of immunosuppressive, Gs protein coupled A2 adenosine receptor subtypes A2A and A2B (A2AR and A2BR, respectively) should prevent the inhibition of anti-tumor T cells and thus facilitate their complete rejection. This hypothesis was prompted by our earlier findings that A2AR and A2BR play a critical role in the protection of normal tissues (e.g., liver and lung) from overactive immune cells in acutely inflamed and hypoxic areas. Our preliminary results confirmed this hypothesis by demonstrating the complete or much improved rejection of large tumors in approximately -60% mice with genetically inactivated A2AR. Our data strongly suggest that both A2AR and A2BR should be inactivated in order to eliminate tumor protection in 100% of mice. Here we propose to take advantage of this new understanding to accomplish the complete rejection of tumors by making anti-tumor T cells resistant to inhibition by tumor-produced adenosine. This will be done via genetic deletion of both A2AR and A2BR in mice, or by treatments of tumor-bearing mice with novel antagonists selective for both A2AR and A2BR or by negative selection of "inhibitable" anti-tumor T cells during expansion in vitro. Unique types of mice-deficient in A2AR or A2BR or both---will be used to test this novel and feasible strategy to improve the immunotherapy of cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preventing the Hypoxia-Adenosinergic Inhibtion of Anti-HIV Immune Response
  • 批准号:
    8043237
  • 项目类别:
  • 资助金额:
    $28.45万
  • 财政年份:
    2010
  • 负责人:
    Michail Sitkovsky
  • 依托单位:
Cancer Immunotherapy by Targeting A2 Adenosine Receptor
  • 批准号:
    8464014
  • 项目类别:
  • 资助金额:
    $20.15万
  • 财政年份:
    2006
  • 负责人:
    Michail Sitkovsky
  • 依托单位:
"Cancer Immunotherapy by Targeting A2 Adenosine Receptor"
  • 批准号:
    7409103
  • 项目类别:
  • 资助金额:
    $21.65万
  • 财政年份:
    2006
  • 负责人:
    Michail Sitkovsky
  • 依托单位:
"Cancer Immunotherapy by Targeting A2 Adenosine Receptor"
  • 批准号:
    7787425
  • 项目类别:
  • 资助金额:
    $21.65万
  • 财政年份:
    2006
  • 负责人:
    Michail Sitkovsky
  • 依托单位: